3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Neoplasms
4
Neoplasms by Site
3
Colorectal Neoplasms
3
Neoplasms, Glandular and Epithelial
2
Neoplasms by Histologic Type
2
Digestive System Neoplasms
2
Digestive System Diseases
2
Carcinoma, Non-Small-Cell Lung
2
Thymus Neoplasms
1
Thoracic Neoplasms
1
Stomach Neoplasms
1
Respiratory Tract Neoplasms
1
Rectal Diseases
1
Pancreatic Neoplasms
1
Pancreatic Diseases
1
Mesothelioma, Malignant
1
Lung Neoplasms
1
Intestinal Neoplasms
1
Intestinal Diseases
1
Glioma
1
Glioblastoma
1
Gastrointestinal Neoplasms
1
Gastrointestinal Diseases
1
Endocrine System Diseases
1
Endocrine Gland Neoplasms
1
Colonic Diseases
1
Carcinoma, Pancreatic Ductal
1
Carcinoma, Hepatocellular
1
Bronchial Neoplasms
1
Advanced Gastrointestinal Cancer
1
Interventions
Carboplatin
106
Pemetrexed
74
Paclitaxel
58
Cisplatin
52
Erlotinib Hydrochloride
51
Radiotherapy
49
Docetaxel
43
Gemcitabine
41
Bevacizumab
41
pembrolizumab
30
Nivolumab
25
Radiosurgery
21
Etoposide
20
durvalumab
13
Cetuximab
13
Specimen Handling
12
Ipilimumab
12
Magnetic Resonance Spectroscopy
11
Gefitinib
11
Vinorelbine
10
Taxes
10
Radiation
10
Albumin-Bound Paclitaxel
10
osimertinib
9
Biopsy
9
vandetanib
8
Topotecan
7
Platinum
7
Irinotecan
7
Drug Therapy
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Lung Neoplasms
×
napabucasin
×
Clear all
NCT02826161
2023-11-15
CanStem43L
Sumitomo Pharma America, Inc.
Phase 3
Terminated
4 enrolled
6 charts